Skip to main content
. 2022 Nov 9;23(22):13784. doi: 10.3390/ijms232213784

Figure 1.

Figure 1

Main downstream oncogenic pathways unleashed by ligand-interaction and dimerization of the transmembrane tyrosine-kinase receptors (TKR) with a potential relevance as therapeutic targets in primary bone tumors: JAK/STAT, PLC/PCK, PI3K/Akt/mTOR, and RAS/RAF/MEK/ERK (MAPK).